BC
AKBA icon

Bridgefront Capital’s Akebia Therapeutics AKBA Stock Holding History

Bridgefront Capital’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-17,189
Closed -$65K – 311
2021
Q2 		$65K Buy
+17,189
New +$57.9K 0.02% 572

Other funds holding AKBA

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Bridgefront Capital's AKBA Position: Q3 2021 in Review

Bridgefront Capital sold out of Akebia Therapeutics (AKBA) in Q3 2021, closing a stake of 17,189 shares — an estimated $65K sold.

Bridgefront Capital first reported a position in AKBA in Q2 2021 and held it in 1 quarter. The position peaked at $65K in Q2 2021. 126 funds tracked by Wall St. Rank hold AKBA as of Q3 2021.

  • Bridgefront Capital reported no remaining Akebia Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Bridgefront Capital sold 17,189 Akebia Therapeutics shares in Q3 2021, an estimated $65K.
  • Bridgefront Capital first reported a position in Akebia Therapeutics in Q2 2021 and held it in 1 quarter.
  • Bridgefront Capital's Akebia Therapeutics position peaked at $65K in Q2 2021.
  • 126 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2021.

Based on Bridgefront Capital's 13F filing for Q3 2021, filed 12 Nov 2021.